Phase I Trial for Pharmacokinetic Characteristics of Factive 200mg Intravenous Formulation (Gemifloxacin 200mg) With Factive 320mg Tablet Formulation (Gemifloxacin 320mg)

Trial Profile

Phase I Trial for Pharmacokinetic Characteristics of Factive 200mg Intravenous Formulation (Gemifloxacin 200mg) With Factive 320mg Tablet Formulation (Gemifloxacin 320mg)

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jan 2014

At a glance

  • Drugs Gemifloxacin (Primary) ; Gemifloxacin (Primary)
  • Indications Acute exacerbations of chronic bronchitis; Acute sinusitis; Bacterial infections; Community-acquired pneumonia; Urinary tract infections
  • Focus Pharmacokinetics
  • Sponsors LG Life Sciences
  • Most Recent Events

    • 14 Jun 2013 New source identified and integrated (ClinicalTrials.gov record: NCT01879007).
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top